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Abstract 
We aimed to (i) develop a population pharmacokinetic model of tacrolimus in Chinese lung transplant 
recipients, and (ii) propose model-based dosing regimens for individualized treatment. We obtained 807 
tacrolimus steady-state whole blood concentrations from 52 lung transplant patients and genotyped CYP3A5*3. 
Population pharmacokinetic analysis was performed using nonlinear mixed-effects modeling. Monte Carlo 
simulations were employed to determine the initial dosing regimens. Tacrolimus pharmacokinetics was 
described by a one-compartment model with first-order absorption and elimination processes. In CYP3A5*3/*3 
70-kg patients with 30% hematocrit and voriconazole-free therapy, the mean estimated apparent clearance was 
13.1 l h-1 with 20.1% inter-subject variability, which was lower than that in Caucasian lung transplant patients 
(17.5–36.5 l h-1). Hematocrit, postoperative days, tacrolimus daily dose, voriconazole concomitant therapy, and 
CYP3A5*3 genotype were identified as significant covariates for tacrolimus clearance. To achieve target trough 
concentration (10–15 ng ml-1) on the 8th day post-transplant, a higher initial dosage than the current regimen of 
0.04 mg kg-1 every 12 hours is recommended for CYP3A5*1/*3 patients without voriconazole concomitant 
therapy. Given the nonlinear kinetics of tacrolimus and large variability, population pharmacokinetic model 
should be combined with therapeutic drug monitoring to optimize individualized therapy.  
 
Keywords: Tacrolimus; Lung transplantation; Population pharmacokinetics; Monte Carlo simulation; Dosage 
optimization  
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1. Introduction 
Tacrolimus, a potent calcineurin inhibitor, represents the cornerstone prophylaxis treatment for graft rejection in 
lung transplantation (Miano et al., 2019). Currently, its use in combination with mycophenolate mofetil and 
corticosteroids can maintain an immunosuppressive regimen in almost 60% of patients, and is preferred over 
cyclosporine A due to its higher long-term graft and patient survival rates (Christie et al., 2010; European 
Association for the Study of the Liver. Electronic address, 2016).  
Tacrolimus is characterized by a bioavailability of only 25% (range 4%–93%) (Jusko et al., 1995; Vanhove 
et al., 2016b), owing to its poor aqueous solubility (1–2 μg ml-1) and low transmembrane permeability in the 
intestine mediated by the P-glycoprotein efflux pump (Lee et al., 2016; Vanhove et al., 2016a). After absorption 
and subsequent entry into circulation, tacrolimus binds to erythrocytes, albumin, and a1-acid glycoprotein 
(>99%), with a remaining unbound fraction below 1% (Jusko et al., 1995; Yu et al., 2018). It is extensively 
metabolized by the cytochrome P450 CYP3A (CYP3A5) isoenzymes in the liver and predominantly excreted in 
the feces, with renal excretion accounting for less than 3% of the parent compound (Moller et al., 1999; Staatz 
and Tett, 2004). 
Although the efficacy of tacrolimus is well established, the drug displays a narrow therapeutic window and 
high intra- and inter-individual pharmacokinetic variability due to multiple factors, such as postoperative time, 
CYP3A5*3 genetic polymorphisms, and concomitant medications (Campagne et al., 2019). Signs of rejection 
and toxicity, including nephrotoxicity, hypertension, and gastrointestinal disorders, induced by tacrolimus are 
common in transplants, leading to a higher risk of morbidity and mortality (Paradela de la Morena et al., 2010; 
Wehbe et al., 2013). To optimize the therapeutic effect and minimize tacrolimus-induced toxicity, therapeutic 
drug monitoring (TDM) is widely used to ensure target whole-blood concentrations, especially during the early 
post-transplant period. However, the effects of various factors on the pharmacokinetics of tacrolimus have not 
been considered in TDM. 
Population pharmacokinetic (popPK) modeling offers a superior approach compared to other 
concentration-time measurements derived from TDM, as it can verify and quantify pharmacokinetic variability 
(Wang et al., 2019). Therefore, a popPK model that contains predictive factors of pharmacokinetic variability 
may help optimize the initial dose of tacrolimus to improve clinical outcomes. Furthermore, combined with a 
Bayesian method, it can assist subsequent dosage adjustments in clinical practice (Staatz and Tett, 2011; Storset 
et al., 2014).  
Over the past two decades, several popPK models have described the pharmacokinetics of tacrolimus in 
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solid organ transplant recipients (Staatz and Tett, 2011). Among these models, only three related to lung 
transplant patients, focusing on stable patients and the pharmacokinetics of whole-blood, total, and unbound 
plasma tacrolimus in unstable patients early after transplantation with and without cystic fibrosis in Europe 
(Monchaud et al., 2012; Saint-Marcoux et al., 2005; Sikma et al., 2019). Cystic fibrosis accounts for 
approximately 16% of lung transplant recipients in Europe (Christie et al., 2010). It also results in a very 
heterogeneous pharmacokinetic behavior of tacrolimus (Sikma et al., 2019). However, given differences in 
etiology of cystic fibrosis and genetic background, this disease has not yet become an indication in Chinese lung 
transplant recipients. Additionally, compared to patients in Europe, Chinese recipients are characterized by an 
older mean age of 57.28 ± 18.59 years (range 15–79 years, with those >60 years accounting for more than 35% 
of cases), more comorbidities, and more risk factors of a poor outcome, including recipient age and preoperative 
mechanical ventilation (Mao et al., 2013; Wallinder et al., 2019). Therefore, very heterogeneous tacrolimus 
pharmacokinetic profiles might define Chinese lung transplant recipients, and no dose individualization based 
on population pharmacokinetic models has been attempted for such patients. 
Based on the above considerations, the present study aimed (i) to develop a popPK model that described 
tacrolimus pharmacokinetics in Chinese lung transplant patients using a retrospectively collected dataset and 
identify any variability to facilitate dose individualization; and (ii) to perform simulations that optimized dosing 
regimens during the early stage of lung post-transplantation. 
 
2. Methods 
2.1. Subjects and clinical data collection 
Patients at the affiliated Wuxi People's Hospital of Nanjing Medical University, who had their first lung 
transplantation between September 2015 and June 2018, and were administrated oral tacrolimus to prevent 
allograft rejection were included in this study. Exclusion criteria comprised serious infections (e.g., septic 
shock), age below 16 years, acute rejection, dialysis treatment, severe gastrointestinal disorders, or a second 
lung transplantation. 
Whole-blood trough concentrations (C0) of tacrolimus, laboratory tests, and concomitant medications were 
retrospectively acquired from the patients’ medical records. Demographic characteristics of the patients, such as 
body weight, height, age, and gender, as well as dosing history and sampling time were also collected. The study 
was approved by the affiliated Wuxi People’s Hospital of Nanjing Medical University Ethics Committee for 
medical research ethics (number: KS202002). All participants gave written informed consent. The study was 
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conducted in accordance with the Declaration of Helsinki (2013). 
 
2.2. Immunosuppressive therapy  
Patients received an immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil, and 
corticosteroids. Oral administration of tacrolimus by immediate-release formulation (Prograf; Astellas Pharma 
Inc, Dublin, Ireland) was commenced at 0.04 mg kg-1 every 12 hours (q12h) under fasting conditions right after 
transplantation. Subsequent doses were empirically adjusted to achieve C0 of 10–15 ng ml-1 in the first 6 months 
post-operation, 8–12 ng ml-1 between 6 and 12 months, and 6–10 ng ml-1 thereafter according to routine TDM, 
clinical evidence of efficacy, and adverse reactions.  
Mycophenolate mofetil (CellCept; Roche Pharma Ltd., Shanghai, China) was given orally at 0.5 g q12h for 
patients with body weight <50 kg and 0.75 g q12h for those ≥50 kg. Intravenous methylprednisolone was 
administered at 500 mg on the day of transplant and 0.5 mg kg-1 day-1 during the first three days post-transplant. 
To maintain the immunosuppressive regimen, prednisolone was given orally at 0.5 mg kg-1 day-1 on the 4th day 
post-transplant and was tapered to 0.25 mg kg-1 day-1 during the first 3 months post-transplant. Thereafter, 
dosage was tapered to 0.15 mg kg-1 day-1 until 9 months post-transplant. One year later, corticosteroid-free 
treatment was administered. Induction therapy was generally used with intravenous basiliximab at 20 mg on the 
day of transplant and on the 4th day post-transplant. 
 
2.3. Blood sample collection and analytical method 
Whole-blood samples were drawn before the morning dose and were assessed by a chemiluminescent 
microparticle immunoassay using the Architect I2000 system (Abbott Laboratories, Abbott Park, IL, USA). 
Experimental procedures were conducted according to the manufacturer’s instructions. Intra- and inter-day 
coefficients of variation were within 10%, with a calibration range between 2.0 and 30 ng ml-1.  
 
2.4. Genotyping  
Ethylenediaminetetraacetic acid-anticoagulated whole blood (2 ml) was obtained from lung transplant recipients 
and sent to Sangon Biotechnology Company (Shanghai, China) for DNA extraction, polymerase chain reaction, 
and subsequent DNA sequencing. Single nucleotide polymorphism of CYP3A5*3 (rs776746) was determined by 
DNA direct sequencing (3730XL; Applied Biosystems, Foster City, CA, USA). Deviation in allele frequencies 
from the Hardy-Weinberg equilibrium was analyzed using Pearson’s chi-square test. Further details are 
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presented in Appendix 1. 
 
2.5. Population pharmacokinetic modeling 
Population pharmacokinetic analysis was performed using a nonlinear mixed-effects modeling software 
(NONMEM®, version 7.4; ICON Development Solutions, Ellicott City, MD, USA) compiled with gfortran 4.6.0 
and interfaced with Perl-speaks--NONMEM (version 4.7.0; uupharmacometrics.github.io/PsN). The NONMEM 
output was analyzed using R software (version 3.5.1; www.r-project.org). First-order conditional estimation 
with interaction between inter-patient variability and residual variability was employed for model development. 
 
2.5.1. Base model development 
Because only trough concentrations were available for analysis, a one-compartment model with first-order 
absorption and elimination was used to describe the pharmacokinetics of tacrolimus. The model was 
parameterized in terms of apparent total clearance (CL/F), apparent volume of distribution (Vd/F), and 
absorption rate constant (Ka). As no sampling was performed during the absorption phase, the Ka was fixed at 
4.48 h-1 based on published data.  
Inter-subject variability was estimated for all parameters except Ka, using the exponential model shown in 
equation (Eq 1): 
Pi = TV (P) × exp (ηi)                                         (Eq 1) 
where Pi is the pharmacokinetic parameter estimation of the ith subject and TV(P) is the typical value of the 
population parameter. ηi is defined as symmetrically distributed inter-subject variability, with a mean of zero 
and a variance of ωi2.  
Residual unexplained variability (RUV) was described using additive (Eq 2), proportional (Eq 3), and 
combined proportional and additive (Eq 4) models. 
Y = F + ε 1                                                    ( Eq 2) 
Y = F + F *ε 1                                                 (Eq 3) 
Y = F + F *ε 1 + ε 2                                            (Eq 4) 
Here, Y is the observed concentration, F is the individual predicted concentration, and εn represents 
symmetrically distributed random variability, with a mean of zero and a variance of σn2. 
 
8 
2.5.2 Covariate analysis 
Potential covariates to be investigated included age, gender, height, body weight, hematocrit, albumin, aspartate 
aminotransferase, total serum bilirubin, creatinine clearance, daily dose of tacrolimus, postoperative days, 
concomitant medications, and genetic polymorphisms of CYP3A5*3. Only comedications >10% in all patients 
were tested. 
Weighted allometric scaling was used to describe CL/F and Vd/F, and account for differences in body size 
and metabolic rate as below (Eq 5):  
Pi = TV(P) × (WTi/70)PWR                                             (Eq 5) 
where Pi represents the pharmacokinetic parameter of the ith individual, WTi represents the body weight of the 
ith individual, and PWR represents the allometric coefficient for the effect of WT on CL/F and Vd/F, which was 
fixed at 0.75 and 1, respectively (Anderson and Holford, 2008). 
Continuous covariates were normalized to the population median values and modeled using linear 
equations (Eq 6–7) and power (Eq 8) as below: 
    Pi = TV(P) + θcov×(COVi/COVmedian)                                     (Eq 6) 
Pi = TV(P) + θcov×(COVi – COVmedian)                                  (Eq 7) 
Pi = TV(P) × (COVi/COVmedian) θ cov                                       (Eq 8) 
where Pi represents the pharmacokinetic parameter of the ith individual, TV(P) is the typical value for the 
parameter, COVi is the covariate value of the ith individual, COVmedian is the population median value of the 
covariate, and θcov is the coefficient term of the covariate effect to be estimated. 
The effect of binary covariates such as CYP3A5*3 polymorphism on parameter P was tested by a scale 
model (Eq 9): 
Pi = TV(P) × (1 + θCYP × CYP)                                          (Eq 9) 
where TV(P) is the typical value for the parameter P in CYP3A5*3/*3 carriers (CYP = 0) and θCYP is the 
fractional change in parameter P in CYP3A5*1/*1 and CYP3A5*1/*3 carriers (CYP = 1). 
Covariates were screened in a stepwise fashion, with forward inclusion and backward elimination. The 
effect of each variable on parameters was investigated using the likelihood ratio. Statistical significance was set 
to P < 0.05, corresponding to an objective function value (OFV) reduction of at least 3.84 for 1 degree of 
freedom in forward inclusion, and to P < 0.01, corresponding to an OFV reduction of at least 6.63 for 1 degree 
of freedom for backward elimination. A covariate without a known pharmacological or biological basis, or with 
<20% effect on a parameter was not retained in the model. Improvement in parameter estimation precision and 
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goodness-of-fit plots, reduction in inter-subject variability and RUV, and stability of the parameter estimates 
were also considered to select the covariates. Finally, the extent of the shrinkage was evaluated in the final 
model.  
 
2.5.3. Model evaluation 
Goodness-of-fit plots, including observed concentrations versus population prediction and individual prediction, 
the conditional weighted residuals versus population prediction, and time after dose, were used to evaluate the 
fitness of the final model to the data. Additionally, nonparametric bootstrap, prediction- and 
variability-corrected visual predictive checks (pvcVPCs), and normalized prediction distribution errors (NPDEs) 
were employed to evaluate the final model. 
For the nonparametric bootstrap procedure, 500 replicate bootstrap data sets were generated from the raw 
database by random resampling and were fitted with the same model to obtain parameter estimates for each 
replicate. The medians and 2.5th–97.5th percentiles of the parameters after bootstrap runs with successful 
convergence were compared with the final model parameter estimates.  
For pvcVPCs, 1000 new data sets were simulated in NONMEM using the final model to produce the 
expected concentrations. Concentration-time profiles were plotted for the 50th, 10th, and 90th percentiles of the 
simulated data and were overlaid with the observed data. 
NPDEs were tested with 3000 simulations for each observation in the raw dataset using the final model. 
NPDE results were summarized statistically and graphically with the NPDE add-on package in R (version 2.0; 
www.npde.biostat.fr). Their distributions were evaluated to test if the final model fully described the observed 
data; plots of NPDEs versus observations and NPDEs versus time were also evaluated. 
 
2.6. Simulation of tacrolimus dosing strategies 
Given how crucial is the target C0 of tacrolimus (10–15 ng ml-1) in the first week post-transplant, Monte Carlo 
simulations were performed to predict the target C0 after 7-day multiple oral doses of different dosing regimens 
based on the final popPK model. The tacrolimus dose was simulated from 0.5 mg q12h to 6 mg q12h for a 
55-kg patient with hematocrit of 30% according to the different CYP3A5*3 genotypes and concomitant 
medication with voriconazole. One thousand simulations were carried out using the initial dataset and 
steady-state C0 of each simulated subject was calculated.  
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3. Results 
3.1. Study population 
A total of 807 whole-blood trough concentrations of tacrolimus collected from 52 lung transplant patients were 
available. The reasons for lung transplantation were idiopathic pulmonary arterial hypertension, chronic 
obstructive pulmonary disease, and idiopathic pulmonary fibrosis. In contrast to previous studies, none of the 
enrolled patients had a cystic fibrosis diagnosis (Monchaud et al., 2012; Sikma et al., 2019). Forty-eight subjects 
were sampled at more than three tacrolimus dose levels with a mean of 25 observations per patient. 
Furthermore, all the recruited patients were co-administered omeprazole and more than half (69.2%) were given 
regular doses of voriconazole during their therapy. The main demographic characteristics of the enrolled 
patients are listed in Table 1. 
The allele frequencies of CYP3A5*3 and CYP3A5*1G genetic polymorphisms are listed in Table 1. There 
were no deviations from the Hardy-Weinberg equilibrium in these two genotypes (P > 0.05). No wild genotype 
of CYP3A5*3 was detected and the frequency of both CYP3A5*1/*3 and CYP3A5*3/*3 was 50% (n = 26). 
 
3.2. Population pharmacokinetic modeling 
A one-compartment model with first-order absorption and elimination was used as the structural model. The 
residual error model using a proportional method was selected. 
The effect of patient body size on the disposal of tacrolimus was described for CL/F and Vd/F by an 
allometric scaling equation based on weight. The inclusion of body weight as a covariate led to a significant 
reduction in OFV by 13.499 points. Furthermore, the daily dose of tacrolimus, hematocrit, and postoperative 
days as continuous covariates, and the co-administration of voriconazole and genetic polymorphisms of 
CYP3A5*3 as discrete covariates, provided a significant decrease of OFV for CL/F. As only trough 
concentrations were available, the Vd/F was not evaluated in the covariate screening. In the backward 
elimination step, all the covariates were retained in the final model. The results of stepwise forward addition and 
backward elimination are shown in Table S1. 
The final model was as follows: 
CL/F = 13.1 × (WT/70)0.75 × (HCT/30)-0.868 × (DD/3)0.616 × (POD/30)0.0807 
          ×1.3 (if CYP3A5*1 carriers) 
          × 0.638 (if with voriconazole comedication)                          (Eq 11) 
Vd/F = 636 × (WT/70)                                                     (Eq 12) 
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where WT is the body weight, HCT is the hematocrit, DD is the daily dose of tacrolimus, POD is the 
postoperative days, and voriconazole is co-therapy with voriconazole. 
The population parameter estimates of CL/F and Vd/F in the final model were 13.1 l h-1 and 636 l, 
respectively. Compared to the base model, all the identified covariates in the final model explained the 38.4% 
inter-subject variability and 13.9% RUV in CL/F. Among covariates, CYP3A5*1/*3 genetic polymorphism 
presented an obvious effect on CL/F; specifically, CL/F was 30.0% faster in patients with CYP3A5*1/*3 than in 
those with CYP3A5*3/*3. Additionally, voriconazole concomitant therapy contributed to a 36.2% lower CL/F 
compared to no treatment. The final model was characterized by clearance showing 20.1% inter-subject 
variability and 32.9% RUV. Shrinkage was estimated at 14.2% for CL/F and 7.7% for Vd/F. All parameter 
precision represented by a standard error was acceptable. Table 2 shows the population pharmacokinetic 
parameter estimates and precision of the final model with covariates. 
 
3.3. Model evaluation 
The goodness-of-fit plots for the base and final model are shown in Figure 1. No significant structural bias and 
obvious systematic deviations were found in the final model, and data fitting was greatly improved compared to 
the base model.  
Bootstrap analysis was successful in 93.4% of the 500 runs. The median values of the pharmacokinetic 
parameter and 2.5%–97.5% estimates obtained from bootstrap were close to those obtained with the original 
dataset with <5% bias, confirming the stability and robustness of the final model (Table 2). 
The pvcVPCs of the final model are presented in Figure 2. The 10th, 50th, and 90th percentiles of the 
observations were within the 95% confidence intervals of the corresponding prediction percentiles for the final 
model, revealing an acceptable agreement between the simulated and observed concentrations at all sampling 
time points. 
The NPDE results are depicted in Figure 3. The quantile-quantile plots and histogram confirmed the 
normality of the NPDE and the good predictability of the final model. The assumption of a normal [0,1] 
distribution for the differences between predictions and observations was acceptable with adjusted P values of 
0.0543 for the global test.  
 
3.4. Dosing strategies 
The results of Monte Carlo simulations are shown in Figure 4. Receiving the current starting dose of 0.04 mg 
12 
kg-1 q12h, 55-kg patients with CYP3A5*3/*3 or CYP3A5*1/*3 carriers, a hematocrit of 30%, and comedication 
with voriconazole, could reach a target steady-state C0 of 10–15 ng ml-1 on the 8th day post-transplant. In 
contrast, for CYP3A5*1/*3 carriers without voriconazole comedication, the current dosage regimen might be 
insufficient. Moreover, to achieve the target concentration, patients co-administered with voriconazole received 
a lower maintenance dose than CYP3A5 non-expressing patients receiving only tacrolimus (1.0–2.0 mg q12h vs. 
≥2.0 mg q12h). Under the designed dosing regimens, over 50% of patients could not achieve the target 
tacrolimus C0 range.  
 
4. Discussion 
To the best of our knowledge, this is the first popPK model for tacrolimus in Chinese lung transplant patients. 
Body weight, hematocrit, postoperative days, daily dose of tacrolimus, CYP3A5*3 polymorphism, and 
concomitant medication with voriconazole were identified as covariates of CL/F. Our study shows that for a 
typical 55-kg patient with CYP3A5*3/*3, with a daily tacrolimus dose of 3 mg, a median of 27 postoperative 
days, and hematocrit of 30%, the CL/F was estimated to be 13.1 l h-1, which is much lower than the published 
value (17.5–36.5 l h-1) for a non-Asian population (Monchaud et al., 2012; Sikma et al., 2019). This discrepancy 
could be explained by the median age of the subjects (54 years, range 16–78 years) being typically higher than 
that of previous studies (41–43 years) (Monchaud et al., 2012; Sikma et al., 2019). Aging is associated with a 
gradual decrease in clearance due to reduced total body water and lean body mass, and a relative increase in 
body fat (Fulop et al., 1985). These changes result in a larger volume available for hydrophobic tacrolimus. 
Additionally, changes in intestinal motility and gastric pH, as well as decreased liver blood flow in older 
patients contribute to a lower clearance of tacrolimus, especially in the first 6 months post-transplantation 
(Jacobson et al., 2012). 
Differences in immunosuppressant regimens, including steroid tapering regimen, concomitant medications, 
and food constituents across medical centers, could lead to variations in the drug’s disposal by influencing the 
action of CYP3A and bioavailability (Fu et al., 2019; Vanhove et al., 2016a). Also, as the analytical method 
may result in bias of parameters estimation (Akbas et al., 2005), the method for assaying tacrolimus C0 may be 
inconsistent with that used in previous studies (Monchaud et al., 2012; Sikma et al., 2019) and give rise to the 
lower estimated CL/F (Brunet et al., 2019). Furthermore, ethnic variations between Chinese and Caucasian 
patients (Staatz et al., 2010; Tang et al., 2016) might be another factor. Polymorphic expression and 
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ethnic-specific distribution or activity of CYP3A5 and ABCB1 alleles have been suggested to play an important 
role in the ethnic variations observed in tacrolimus pharmacokinetics (Campagne et al., 2019; Dirks et al., 
2004). In this as well as in previous studies on lung transplantation, only the impact of CYP3A5*3 genotypic 
variants has been explored; CYP3A5*6 and *7 variants and ABCB1 genotypes with inter-ethnic comparisons 
have not been included.  
Interestingly, the incorporation of daily drug dose as a covariate significantly improved data fitting by 
decreasing the OFV by 298.208 points, indicating nonlinear clearance of the drug in lung transplant patients. 
The CL/F of tacrolimus increased nonlinearly with higher daily drug doses, which is in agreement with previous 
reports in kidney and liver transplant recipients (Ahn et al., 2005; Zhao et al., 2016). Such nonlinear kinetics can 
be explained by poor water solubility and low transmembrane permeability of tacrolimus in the intestine. These 
properties cause a dissolution rate-limited absorption in the gastrointestinal tract, as well as variable and low 
oral bioavailability (Lee et al., 2016). Further research with a larger sample size and intensive sampling will 
provide a more specific picture of the nonlinear behavior of tacrolimus kinetics in lung transplantations. 
Weight was identified as a significant covariate on tacrolimus pharmacokinetics in lung transplant patients. 
A positive relationship was found between body weight and CL/F and Vd/F , indicating that a higher 
weight-normalized dose of tacrolimus was required at increasing body weight.  
A negative relationship was found here between tacrolimus CL/F and the hematocrit after lung 
transplantation. This may be explained by the strong binding of tacrolimus to erythrocytes, facilitated by the 
drug’s lipophilicity and the presence of immunophilins in red blood cells (Vanhove et al., 2016a). A lower 
hematocrit commonly leads to a transiently increased unbound fraction of tacrolimus, resulting in a higher 
clearance and subsequent higher tacrolimus daily dose requirement as more tacrolimus is metabolized and 
eliminated from the body. 
Postoperative days has been identified as a major surrogate for many time-dependent variables (Pou et al., 
1998). Here, a gradual improvement in metabolic function with postoperative days increased the CL/F after lung 
transplantation. This may be attributed to the progressive recovery of CYP3A enzyme activity in the intestine 
and liver and the tapering of corticosteroid doses with increasing time after transplantation, particularly during 
the initial postoperative period. Other factors and possible mechanisms related to the effect of postoperative 
days on tacrolimus pharmacokinetics remain to be determined. 
Various studies have shown that CYP3A5*3 polymorphism is associated with the pharmacokinetics of 
tacrolimus (Wang, 2009; Zheng et al., 2004). Our observation further confirmed these findings and 
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demonstrated that CL/F of tacrolimus for lung transplant patients was 1.3-fold higher in CYP3A5*1 carriers than 
in non-carriers (CYP3A5*3/*3), which is similar to the published value of 1.4-fold (Monchaud et al., 2012). 
Introduction of this covariate accounted for 10% of inter-subject variability in tacrolimus clearance, which is 
close to the value of 6% reported in the literature (Jacobson et al., 2011). Therefore, given the wide availability 
of TDM, genetic testing prior to initiating tacrolimus treatment is important for dosage optimization.  
Besides genetic factors, concomitant medications usually lead to drug-drug interactions involving 
tacrolimus. These contribute to the observed variability of pharmacokinetics in lung transplantations as they 
affect CYP3A- and P-glycoprotein-mediated metabolism (Christians et al., 2002). Voriconazole, an inhibitor of 
CYP3A activity in both the intestine and the liver, is frequently administered to lung transplant recipients 
(Huang et al., 2020). Here, its administration led to a 36.2% slower clearance relative to voriconazole-free 
patients. Its inhibition of intestinal and hepatic CYP3A enzymes reduced tacrolimus clearance, resulting in a 
higher concentration of tacrolimus, which is consistent with findings in patients with primary nephrotic 
syndrome (Huang et al., 2020). Thus, TDM should be conducted before the administration of voriconazole, and 
the dosage regimen should be adjusted according to the target tacrolimus concentration. 
Wuzhi capsule and calcium channel blockers are extensively used as a tacrolimus-sparing agent (Li et al., 
2011). They were not included as covariates in the final model due to the small patient size. Corticosteroids are 
also regarded as important inducers of CYP3A and P-glycoprotein, and are likely to affect the disposal of 
tacrolimus. However, they were also not included in the final model, probably due to the low dose of 
co-administered steroids (18.67 ± 25.95 mg day-1 in the form of prednisone). 
For the population in this study, most concentrations were taken at steady-state trough time-points and in 
the clinic, where the dose of tacrolimus is normally adjusted according to the monitored C0 (10–15 ng ml-1). 
Therefore, the current study used the developed final model to predict the C0 of tacrolimus and test the possible 
clinical impact of CYP3A5 genotype and concomitant medication with voriconazole. Simulation results 
demonstrated a high variability in tacrolimus pharmacokinetics, whose origin remains unknown. Moreover, they 
indicated that the present initial dose of 0.04 mg kg-1 q12h was insufficient for a 55-kg patient with hematocrit 
of 30%, CYP3A5*1/*3, and receiving voriconazole-free treatment to reach the target concentration range.  
There are some limitations in this study. The first and most obvious one is the relatively small sample size. 
A second limitation is the incorporation of trough concentrations only, which were employed to reliably assess 
CL/F and its covariates. A third limitation is the lack of an evaluation of the relationship between efficacy or 
toxicity and tacrolimus trough concentrations. Linking the pharmacokinetics to clinical outcomes with the aim 
15 
of targeting a more appropriate therapeutic range remains a critical but challenging aspect of tacrolimus therapy. 
Despite all the above limitations, the study can provide the theoretical basis for personalized tacrolimus 
treatment and serve as a valuable reference for lung transplantations. 
 
5. Conclusion 
In this study, a popPK model to characterize the pharmacokinetics of tacrolimus was developed for the first time 
in Chinese lung transplant patients. Significant covariates, including hematocrit, postoperative days, daily dose 
of tacrolimus, concomitant medication with voriconazole, and CYP3A5*3 genotypes, were identified in the final 
model. This study highlights a lower tacrolimus clearance in Chinese lung transplant patients than in 
Caucasians. The discrepancy might be attributed to ethnic variation and different age composition of the 
samples. Another important discovery is the identification of an underlying nonlinear kinetics of tacrolimus. 
CYP3A5*1/*3 55-kg patients with 30% hematocrit and voriconazole-free therapy require a higher initial dose 
than the current regimen (0.04 mg kg-1 q 12 h) to achieve the target concentration. The unknown high variability 
in tacrolimus pharmacokinetics revealed by the simulation results suggests that popPK model should be 
combined with traditional TDM to optimize dose regimens to reach target trough tacrolimus levels more 
effectively.  
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Figure legends 
Figure 1 Goodness-of-fit plots for the base model and the final model. A. Observed versus population predicted 
concentration, B. observed versus individual predicted concentration, C. conditional weighted residuals 
(CWRES) versus population predictions, and D. CWRES versus time after dose. The solid lines in A and B are 
identity lines, and the solid lines in C and D are zero lines. 
 
Figure 2 Prediction- and variability-corrected visual predictive check (pvcVPC) plot of the final 
pharmacokinetic model. The red solid line represents the prediction- and variability-corrected median observed 
concentration, and the semitransparent red shaded area represents the simulation-based 95% confidence 
intervals (CIs) for the median. The red dashed lines represent the corrected observed 10th and 90th percentiles, 
and the semitransparent blue shaded areas represent the simulation-based 95% CIs for the corresponding 
predicted percentiles from the final model. The blue dots represent the prediction- and variability-corrected 
observations. 
 
Figure 3 Normalized prediction distribution error (NPDE) plot of the final model. A. Quantile-quantile plot of 
the distribution of the NPDE against the theoretical distribution (semitransparent blue fields), B. Histogram of 
the distribution of the NPDE against the theoretical distribution (semitransparent blue fields), C. NPDE vs. 
postoperative time (days), D. NPDE vs. predicted concentrations. In plot C and D, the red solid lines represent 
the median NPDE of the observations, and semitransparent red fields represent the simulation-based 95% 
confidence intervals (CIs) for the median. Blue solid lines represent the NPDE of the observed 5th and 95th 
percentiles, and semitransparent blue fields represent the simulation-based 95% CIs for the corresponding 
predicted percentiles from the final model. The blue dots represent the NPDE of the observations. 
 
Figure 4 Boxplots of the distributions of simulated tacrolimus trough concentrations for CYP3A5*1/*3 and 
*3/*3 with co-administered voriconazole on 0.5, 1, 1.5, 2, 2.5, and 3 mg q12h, and for non-combined 
voriconazole group on 1, 2, 3, 4, 5, and 6 mg q12h regimens in lung transplant patients. The bold horizontal bars 
in the middle show the median values, whereas the outer boundaries of the boxes represent the ranges of the 25th 
and 75th percentiles (interquartile ranges). The whiskers indicate the maximum and the minimum values of 
trough concentrations.  
Tables 
Table 1 Characteristics of lung transplant recipients used for model development 
Characteristics Number or Mean ± SD Median (Range) 
No. of patients (Male/Female) 52 (37/15) / 
No. of tacrolimus samples 807 / 
Age (years) 51.66±15.04 54 (16-78) 
Height (m) 1.67±0.08 1.69 (1.43-1.83) 
Total body weight, WT (kg) 53.77±10.9 55 (32-75) 
Predicted fat free mass, FFM (kg) a 43.16±9.33 46.17 (20.87-59.9) 
Hemoglobin, HB (g l-1) 99.16±16.52 98 (21-149) 
Haematocrit, HCT (%) 29.71±4.58 29.3 (18-41.7) 
Total serum protein, TP (g l-1) 61.2±7.23 60.5 (43.5-92.2) 
Serum albumin, ALB (g l-1) 38.47±6.35 38 (24.6-59.5) 
Alanine transaminase, ALT (U l-1) 20.01±21.88 14 (2-289) 
Aspartate aminotransferase, AST (U l-1) 21.75±25.59 16 (5-348) 
Alkaline phosphatase, ALP (U 1-1) 71.3±41.87 65 (20-757) 
γ-Glutamyl transpeptidase, γ-GGT (U 1-1) 36.5±49.01 20 (4-678) 
Total serum bilirubin, TBIL (μmol 1-1) 18.84±14.67 14.6 (3.8-157.5) 
Blood uric nitrogen, BUN (mmol 1-1) 9.01±5.45 7.5 (0.5-42.6) 
Serum creatinine, SCR (μmol 1-1) 73.11±42.62 63.9 (19.9-561.3) 
Creatinine clearance, CCR (m1 min-1) a 89.16±38.56 83.64 (11.06-289.29) 
Methylprednisolone dose (mg day-1) 18.67±25.95 16(6-524) 
  Continues 
Table 1 continued   
Characteristics Number or Mean ± SD Median (Range) 
Sampling time (Postoperative days), POD (day) 35.79±30.62 27 (2-162) 
Tacrolimus daily dose (mg day-1) 3.8±2.58 3 (0.125-13) 
Tacrolimus trough concentration (ng m1-1) 10.82±4.59 10.3 (1.2-29.7) 
Concomitant medication b   
        Wuzhi capsule 11 / 
        Calcium channel blocker 
 
13  / 
        Voriconazole 285 / 
Methylprednisolone  807 / 
Mycophenolate mofetil 191 / 
Genotype, n (%) c   
CYP3A5*3 (A6986G, rs776746)   
GA (*1/*3) 26 (50.0%) / 
GG (*3/*3) 26 (50.0%) / 
SD, standard deviation 
a Calculated from serum creatinine using the Cockcroft-Gault formula: CCR= [140 – age (years)] × weight (kg) / [0.818 × SCR (μmol l-1)] × (0.85, if female) 
b Data are expressed as number of samples 
c All allele frequencies were in agreement with those predicted by Hardy-Weinberg equation (P > 0.05). 
  
Table 2 Population pharmacokinetic parameter estimates of the base model, final model, and bootstrap 
Parameter 
Base model Final model Bootstrap of final model Bias 
(%) Estimate RSE (%) Estimate RSE (%) Median 2.5%-97.5% 
ka (h-1) 4.48 / 4.48 / 4.48 / / 
CL*(Body weight/70)0.75/F (l h-1) 9.93 8.4 13.1 4.8 13.1 11.8-14.5 0.00 
CYP3A5*1*3 / / 0.3 28.2 0.310 0.158 - 0.499 3.33 
Haematocrit / / -0.868 18.5 -0.871 -1.202 - (-0.504) 0.34 
Postoperative days / / 0.0807 29.0 0.084 0.036 - 0.129 4.09 
Daily dose of tacrolimus / / 0.616 8.4 0.613 0.518 - 0.706 -0.49 
Co-therapy with Voriconazole / / -0.362 11.8 -0.366 -0.451 - (-0.248) 1.10 
Vd* (Body weight/70)/F (l) 1160 13.6 636 15.3 642 435 - 960 0.94 
Between-subject variability        
CL/F (%) 58.5 9.9 20.1 14.9 19.3 13.7 - 24.9 -3.98 
Shirinkage (%) 3.4 / 14.2 / / / / 
Vd/F (%) 93.8 11.1 98.2 9.9 96.4 68.5 - 113.7 -1.83 
Shirinkage (%) 8.5 / 7.7 / / / / 
Residual variability        
Proportional error (%) 46.8 8.9 32.9 8.1 32.6 29.8 - 35.4 -0.91 
Shirinkage(%) 4.0 / 4.1 / / / / 
RSE, relative standard error; Bias% = (Bootstrap – NONMEM) / NONMEM × 100% 
Base model Final model
Figure 1
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Appendix S1. Genotyping of CYP3A5*3 single-nucleotide polymorphisms. 
DNA was extracted from the whole blood of both liver transplant receipients and their corresponding donors using the TIANamp 
Blood DNA Kit (Tiangen Biotech Co. Ltd, Beijing, China). The polymerase chain reaction (PCR) was applied to amplify the 
variant alleles using ABI Veriti 96-Well PCR (Applied Biosystems, Foster City, CA, USA). The volume of amplification reaction 
was 20 μl, containing 10 μl 2×Taq Master Mix, 7 μl of distilled water, 1 μl of each primer (10 pmol μl-1), and 1 μl DNA template 
(20 ng μl-1). The sequences of forward (F) and reverse (R) primers were listed below.  
 
The sequences of forward (F) and reverse (R) primers for the CYP3A5 genotyping SNPs 
Gene Primer                                                Tm 
F: 5’ CATTTAGTCCTTGTGAGCACTTGAT 3’              59.9 ℃ CYP3A5*3 
(rs776746) R: 5’ TAGCACTGTTCTGATCACGTCG 3’                  58.8 ℃ 
 
The PCR conditions were as follows: a denaturation at 95 oC for 3 minutes, then 35 cycles of denaturation at 94 oC for 30 
seconds, annealing at 55 oC for 25 seconds, and elongation at 72 oC for 30 seconds, followed by a final extension at 72 oC 
for 5 minutes. The amplified DNA was purified and genotypes were determined by direct sequencing using ABI PRISM 
3730XL Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Tm, melting temperature. 
  
Supplementary table 
Table S1  Forward inclusion and backward elimination process 
Model number Model description OFV ΔOFV Significant 
1 Base model 3730.767   
 Forward inclusion    
2 Add WT on CL and V in model 1 3717.092 -13.675 YES 
3 ADD HCT on CL in model 2 3613.327 -103.765 YES 
4 ADD CYP3A5 on CL in model 3 3594.822 -18.505 YES 
5 ADD co-therapy with voriconazole on CL in model 4 3334.359 -260.463 YES 
6 ADD POD on CL in model 5 3285.589 -48.77 YES 
7 ADD DD on CL in model 6 2987.381 -298.208 YES 
8 ADD ALB on CL in model 7 2986.457 -0.924 NO 
 Backward elimination    
9 Remove HCT on CL from model 7 3055.428 68.047 YES 
10 Remove CYP3A5 on CL from model 7 2994.707 7.328 YES 
11 Remove co-therapy with voriconazole on CL from model 
7 
3079.030 91.649 YES 
12 Remove POD on CL from model 7 3016.719 29.338 YES 
13 Remove DD on CL from model 7 3285.589 298.208 YES 
